Cencora (COR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $4.48
- Estimate
- $4.35
- Surprise
- +3.0%
- Revenue (period 2026-06-30)
- $84.75B
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
Cencora (COR) beat the $4.35 estimate with adjusted EPS of $4.48 — a clear 3.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates COR Sell at 5.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +3.0% surprise compares with a +1.5% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Customer: top ten customers (66.0%)
- Target reached (-5.7% upside)
- Quality below floor (3.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $341.41
- Price target
- $392.62
- Stop
- $325.79
- Upside to target
- +15.0%
The stock trades at 24.5× trailing but 17.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 80 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
COR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Distribution
- Market cap
- $64.15B
- P/E (fwd)
- 17.0
- P/E (ttm)
- 24.5
- 52-week range
- $244.82–$377.54
- Off 52-week high
- 9.6%
- RSI (14)
- 80
- Volume vs avg
- 1.24×
- Score today
- 5.2/10